



A Brighter Future for Mental Health

CSE: MBIO

MINDBIO ANNOUNCES INTENTION TO REFILE MD&A

Vancouver, British Columbia – February 14, 2025 – MindBio Therapeutics Corp. (the “Company” or “MindBio”) (CSE: MBIO; Frankfurt: WF6) announces that, pursuant to Section 11.5 of National Instrument 51-102 - *Continuous Disclosure Obligations*, and as a result of a review by the British Columbia Securities Commission, it plans to amend and refile its interim management’s discussion and analysis (“MD&A”) for the period ended December 31, 2024 and its annual MD&A for the year ended June 30, 2024 (the “MD&A”, and as amended, the “Amended MD&A”) to clarify its disclosure. The Amended MD&A is expected to provide revised and updated disclosure respecting, among other things, the Company’s overall performance, operations, liquidity and capital resources, investor loans, management compensation and related party transactions. The Company will also refile its interim financial statement and related officer’s certificates for the period ended December 31, 2024 in order to correct certain errors (the “Amended Financial Statements”).

The changes noted above will be intended to enhance and update the disclosure that was included in the originally filed MD&A and provide readers with a more detailed discussion of the Company’s operations. The Company intends to file the Amended MD&A and Amended Financial Statements as soon as possible and will issue another press release announcing the same upon the filing date.

For further information, please contact:

Justin Hanka, Chief Executive Officer
61 433140886
justin@mindbiotherapeutics.com

Media Inquiries

Kristina Spionjak
pr@hlthcommunications.com

Cautionary Note Concerning Forward-Looking Statements:

This news release may contain certain “forward-looking statements” within the meaning of applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target”, “plan”, “forecast”, “may”, “schedule” and other similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to the anticipated timing for the filing of the Amended MD&A and Amended Financial Statements. Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements and information other than as required by applicable laws, rules and regulations.

Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.